Cicero-Sarmiento, C.G.; Ortiz-Andrade, R.; Araujo-León, J.A.; Segura-Campos, M.R.; Vazquez-Garcia, P.; Rubio-Zapata, H.; Hernández-Baltazar, E.; Yañez-Pérez, V.; Sánchez-Recillas, A.; Sánchez-Salgado, J.C.;
et al. Preclinical Safety Profile of an Oral Naringenin/Hesperidin Dosage Form by In Vivo Toxicological Tests. Sci. Pharm. 2022, 90, 28.
https://doi.org/10.3390/scipharm90020028
AMA Style
Cicero-Sarmiento CG, Ortiz-Andrade R, Araujo-León JA, Segura-Campos MR, Vazquez-Garcia P, Rubio-Zapata H, Hernández-Baltazar E, Yañez-Pérez V, Sánchez-Recillas A, Sánchez-Salgado JC,
et al. Preclinical Safety Profile of an Oral Naringenin/Hesperidin Dosage Form by In Vivo Toxicological Tests. Scientia Pharmaceutica. 2022; 90(2):28.
https://doi.org/10.3390/scipharm90020028
Chicago/Turabian Style
Cicero-Sarmiento, Carla Georgina, Rolffy Ortiz-Andrade, Jesús Alfredo Araujo-León, Maira Rubà Segura-Campos, Priscila Vazquez-Garcia, Héctor Rubio-Zapata, Efrén Hernández-Baltazar, Victor Yañez-Pérez, Amanda Sánchez-Recillas, Juan Carlos Sánchez-Salgado,
and et al. 2022. "Preclinical Safety Profile of an Oral Naringenin/Hesperidin Dosage Form by In Vivo Toxicological Tests" Scientia Pharmaceutica 90, no. 2: 28.
https://doi.org/10.3390/scipharm90020028
APA Style
Cicero-Sarmiento, C. G., Ortiz-Andrade, R., Araujo-León, J. A., Segura-Campos, M. R., Vazquez-Garcia, P., Rubio-Zapata, H., Hernández-Baltazar, E., Yañez-Pérez, V., Sánchez-Recillas, A., Sánchez-Salgado, J. C., Hernández-Núñez, E., & Ruiz-Ciau, D.
(2022). Preclinical Safety Profile of an Oral Naringenin/Hesperidin Dosage Form by In Vivo Toxicological Tests. Scientia Pharmaceutica, 90(2), 28.
https://doi.org/10.3390/scipharm90020028
